About us new hero

About us

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Read more

Arthur, Oncology Scientist, US

Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

Our strategy is to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.

Our values and expectations are at the heart of everything we do and form an important part of our culture.
Our values are Patient focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.

What we do

We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Pharmaceuticals

Immune system T-cells attacking a cancer cell

Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.

Vaccines

Herpes zoster virus of shingles

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.

Consumer Healthcare

Novamin, a key technology in Sensodyne Repair and Protect

Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Nutrition/gastro-intestinal and Skin health categories.

How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.
 

  • £3.9bn

    R&D investment in 2017

  • 3

    significant approvals in 2017 – Shingrix, Trelegy Ellipta and Juluca

  • £6.7bn

    new product sales in Pharmaceuticals and Vaccines in 2017

  • 13%

    Consumer Healthcare sales in 2017 from product innovations launched over the past three years

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.
 

  • £30.2bn

    total turnover in 2017

  • £8.6bn

    adjusted operating profit in 2017

  • £3.4bn

    free cash flow in 2017

  • £3.9bn

    dividends paid in 2017

Trust

We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.
 

  • 85%

    of employees proud to work at GSK

  • £261.6m

    donated in 2017 to local communities through product donations, time and cash

  • 1st

    in Access to Medicines Index all 5 times since its launch in 2008

Find out more about us